AURX · Nuo Therapeutics, Inc. · Documents
$1.25
-0.01 (-0.79%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe based on the operating cash requirements and capital expenditures expected for the next twelve months that our current resources and projected revenue from sales of Aurix products and the Private Label product to Smith+Nephew are insufficient to support our operations for the next 12 months from the date these financial statements are issued. As such, we believe that substantial doubt about our ability to continue as a going concern exists.”View the 10-Q filed Aug 14, 2026
Market Cap
$61.03M
Shares
48.43M
Volume · Oct 20
1652
Avg daily vol (3M)
6665
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 8-K | — | 2022-05-02 | 2022-04-29 | |
| 10-K | — | 2022-04-15 | 2021-12-31 | |
| NT 10-K | — | 2022-03-31 | 2021-12-31 | |
| SC TO-T/A | — | 2022-03-21 | — | |
| SC 14D9 | — | 2022-02-04 | — | |
| SC TO-T | — | 2022-01-21 | — | |
| 8-K | — | 2022-01-04 | 2021-12-01 | |
| 8-K | — | 2021-04-21 | 2021-04-20 | |
| 8-K | — | 2020-10-06 | 2020-10-05 | |
| 8-K | — | 2020-04-13 | 2020-04-03 | |
| 8-K | — | 2020-03-30 | — | |
| 10-Q | — | 2020-01-31 | 2019-09-30 |
Showing 51–62 of 62 filings